Top

31-01-2025 | Disseminated Intravascular Coagulation | Progress in Hematology

Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024: part 4—trauma, burn, obstetrics, acute pancreatitis/liver failure, and others

Authors: Mineji Hayakawa, Yoshinobu Seki, Takayuki Ikezoe, Kazuma Yamakawa, Kohji Okamoto, Shigeki Kushimoto, Yuichiro Sakamoto, Yuki Itagaki, Yuki Takahashi, Hiroyasu Ishikura, Toshihiko Mayumi, Toshihisa Tamura, Kenji Nishio, Yu Kawazoe, Ayami Shigeno, Yudai Takatani, Akihito Tampo, Yoshihiko Nakamura, Katsunori Mochizuki, Noritaka Yada, Kaoru Kawasaki, Akira Kiyokawa, Mamoru Morikawa, Mitsuhiro Uchiba, Takeshi Matsumoto, Hidesaku Asakura, Seiji Madoiwa, Toshimasa Uchiyama, Shinya Yamada, Shin Koga, Takashi Ito, Toshiaki Iba, Noriaki Kawano, Satoshi Gando, Hideo Wada, Committee of the Clinical Practice Guidelines for Disseminated Intravascular Coagulation 2024, the Japanese Society on Thrombosis, Hemostasis

Published in: International Journal of Hematology

Abstract

Disseminated intravascular coagulation (DIC) is a complex condition with diverse etiologies. While its association with sepsis has been widely studied, less focus has been given to DIC arising from other critical conditions, such as trauma, burns, acute pancreatitis, and obstetric complications. The 2024 Clinical Practice Guidelines, developed by the Japanese Society on Thrombosis and Hemostasis (JSTH), aim to fill this gap and offer comprehensive recommendations for managing DIC across various conditions. This study, Part 4 of the guideline series, addresses DIC management in trauma, burns, obstetric complications, acute pancreatitis/liver failure, viral infections, and autoimmune diseases. For trauma-associated DIC, early administration of fresh-frozen plasma (FFP), coagulation factor concentrates such as fibrinogen and prothrombin complex concentrates, and tranexamic acid is recommended. The guidelines also highlight DIC in obstetrics, which is associated with massive bleeding, and recommend the administration of fibrinogen concentrate, antithrombin concentrate, and tranexamic acid. Through a systematic review of the current evidence, the guidelines provide stratified recommendations aimed at improving clinical outcomes in DIC management beyond sepsis, thereby serving as a valuable resource for healthcare providers globally.

Wada H, Asakura H, Okamoto K, Iba T, Uchiyama T, Kawasugi K, et al. Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res. 2010;125(1):6–11. https://doi.org/10.1016/j.thromres.2009.08.017.CrossRefPubMed

Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol. 2009;145(1):24–33. https://doi.org/10.1111/j.1365-2141.2009.07600.x.CrossRefPubMed

Di Nisio M, Baudo F, Cosmi B, D’Angelo A, De Gasperi A, Malato A, et al. Diagnosis and treatment of disseminated intravascular coagulation: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res. 2012;129(5):e177–84. https://doi.org/10.1016/j.thromres.2011.08.028.CrossRefPubMed

Hayakawa M, Maekawa K, Kushimoto S, Kato H, Sasaki J, Ogura H, et al. Hyperfibrinolysis in severe isolated traumatic brain injury may occur without tissue hypoperfusion: a retrospective observational multicentre study. Crit Care. 2017;21(1):222. https://doi.org/10.1186/s13054-017-1811-1.CrossRefPubMedPubMedCentral

Hayakawa M, Maekawa K, Kushimoto S, Kato H, Sasaki J, Ogura H, et al. High D-dimer levels predict a poor outcome in patients with severe trauma, even with high fibrinogen levels on arrival: a multicenter retrospective study. Shock. 2016;45(3):308–14. https://doi.org/10.1097/SHK.0000000000000542.CrossRefPubMed

Hayakawa M, Gando S, Ono Y, Wada T, Yanagida Y, Sawamura A. Fibrinogen level deteriorates before other routine coagulation parameters and massive transfusion in the early phase of severe trauma: a retrospective observational study. Semin Thromb Hemost. 2015;41(1):35–42. https://doi.org/10.1055/s-0034-1398379.CrossRefPubMed

Floccard B, Rugeri L, Faure A, Saint Denis M, Boyle EM, Peguet O, et al. Early coagulopathy in trauma patients: an on-scene and hospital admission study. Injury. 2012;43(1):26–32. https://doi.org/10.1016/j.injury.2010.11.003.CrossRefPubMed

Moore HB, Gando S, Iba T, Kim PY, Yeh CH, Brohi K, et al. Defining trauma-induced coagulopathy with respect to future implications for patient management: communication from the SSC of the ISTH. JTH. 2020;18(3):740–7. https://doi.org/10.1111/jth.14690.CrossRefPubMed

Kornblith LZ, Moore HB, Cohen MJ. Trauma-induced coagulopathy: the past, present, and future. JTH. 2019. https://doi.org/10.1111/jth.14450.CrossRefPubMed

10.

Gando S, Otomo Y. Trauma-induced coagulopathy: the past, present, and future: a comment. JTH. 2019;17(9):1567–9. https://doi.org/10.1111/jth.14520.CrossRefPubMed

11.

Wada T, Yamakawa K. Trauma-induced coagulopathy: the past, present, and future: a comment. JTH. 2019;17(9):1571–4. https://doi.org/10.1111/jth.14571.CrossRefPubMed

12.

Rossaint R, Afshari A, Bouillon B, Cerny V, Cimpoesu D, Curry N et al. The European guideline on management of major bleeding and coagulopathy following trauma: sixth edition. Crit Care. 2023; 27(1): 80. https://doi.org/10.1186/s13054-023-04327-7.

13.

Holcomb JB, Tilley BC, Baraniuk S, Fox EE, Wade CE, Podbielski JM, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015;313(5):471–82. https://doi.org/10.1001/jama.2015.12.CrossRefPubMedPubMedCentral

14.

Sabouri M, Vahidian M, Sourani A, Mahdavi SB, Tehrani DS, Shafiei E. Efficacy and safety of fibrinogen administration in acute post-traumatic hypofibrinogenemia in isolated severe traumatic brain injury: a randomized clinical trial. J Clin Neurosci. 2022;101:204–11. https://doi.org/10.1016/j.jocn.2022.05.016.CrossRefPubMed

15.

Lucena LS, Rodrigues RDR, Carmona MJC, Noronha FJD, Oliveira HP, Lima NM, et al. Early administration of fibrinogen concentrate in patients with polytrauma with thromboelastometry suggestive of hypofibrinogenemia: a randomized feasibility trial. Clin. 2021;76:e3168. https://doi.org/10.6061/clinics/2021/e3168.CrossRef

16.

Akbari E, Safari S, Hatamabadi H. The effect of fibrinogen concentrate and fresh-frozen plasma on the outcome of patients with acute traumatic coagulopathy: a quasi-experimental study. Am J Emerg Med. 2018;36(11):1947–50. https://doi.org/10.1016/j.ajem.2018.02.018.CrossRefPubMed

17.

Jehan F, Aziz H, OʼKeeffe T, Khan M, Zakaria ER, Hamidi M et al. The role of four-factor prothrombin complex concentrate in coagulopathy of trauma: a propensity matched analysis. J Trauma Acute Care Surg. 2018; 85(1):18–24. https://doi.org/10.1097/TA.0000000000001938.

18.

Joseph B, Khalil M, Harrison C, Swartz T, Kulvatunyou N, Haider AA, et al. Assessing the efficacy of prothrombin complex concentrate in multiply injured patients with high-energy pelvic and extremity fractures. J Orthop Trauma. 2016;30(12):653–8. https://doi.org/10.1097/BOT.0000000000000665.CrossRefPubMed

19.

Innerhofer P, Fries D, Mittermayr M, Innerhofer N, von Langen D, Hell T, et al. Reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh-frozen plasma (RETIC): a single-centre, parallel-group, open-label, randomised trial. Lancet Haematol. 2017;4(6):e258–71. https://doi.org/10.1016/S2352-3026(17)30077-7.CrossRefPubMed

20.

Yao D, Li Y, Wang J, Yu W, Li N, Li J. Effects of recombinant activated factor VIIa on abdominal trauma patients. Blood Coagul Fibrinolysis. 2014;25(1):33–8. https://doi.org/10.1097/mbc.0000000000000021.CrossRefPubMed

21.

Brown CV, Foulkrod KH, Lopez D, Stokes J, Villareal J, Foarde K, et al. Recombinant factor VIIa for the correction of coagulopathy before emergent craniotomy in blunt trauma patients. J Trauma. 2010;68(2):348–52. https://doi.org/10.1097/TA.0b013e3181bbfb6b.CrossRefPubMed

22.

Stein DM, Dutton RP, Kramer ME, Scalea TM. Reversal of coagulopathy in critically ill patients with traumatic brain injury: recombinant factor VIIa is more cost-effective than plasma. J Trauma. 2009; 66(1): 63–72. https://doi.org/10.1097/TA.0b013e318191bc8a (discussion 3–5).

23.

Yuan Q, Wu X, Du ZY, Sun YR, Yu J, Li ZQ, et al. Low-dose recombinant factor VIIa for reversing coagulopathy in patients with isolated traumatic brain injury. J Crit Care. 2015;30(1):116–20. https://doi.org/10.1016/j.jcrc.2014.07.009.CrossRefPubMed

24.

Collaborators Crash-trial, Shakur H, Roberts I, Bautista R, Caballero J, Coats T et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010; 376(9734): 23–32. https://doi.org/10.1016/S0140-6736(10)60835-5.

25.

Crash-trial C. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. Lancet. 2019;394(10210):1713–23. https://doi.org/10.1016/S0140-6736(19)32233-0.CrossRef

26.

Ng W, Jerath A, Wąsowicz M. Tranexamic acid: a clinical review. Anaesthesiol Intensive Ther. 2015;47(4):339–50. https://doi.org/10.5603/AIT.a2015.0011.CrossRefPubMed

27.

Ker K, Roberts I, Shakur H, Coats TJ. Antifibrinolytic drugs for acute traumatic injury. Cochrane Database Syst Rev. 2015; 2015(5): Cd004896. https://doi.org/10.1002/14651858.CD004896.pub4.

28.

Lavrentieva A, Kontakiotis T, Bitzani M, Papaioannou-Gaki G, Parlapani A, Thomareis O, et al. Early coagulation disorders after severe-burn injury: impact on mortality. Intensive Care Med. 2008;34(4):700–6. https://doi.org/10.1007/s00134-007-0976-5.CrossRefPubMed

29.

García-Avello A, Lorente JA, Cesar-Perez J, García-Frade LJ, Alvarado R, Arévalo JM, et al. Degree of hypercoagulability and hyperfibrinolysis is related to organ failure and prognosis after burn trauma. Thromb Res. 1998;89(2):59–64. https://doi.org/10.1016/s0049-3848(97)00291-0.CrossRefPubMed

30.

Aoki K, Aikawa N, Sekine K, Yamazaki M, Mimura T, Urano T et al. Elevation of plasma free PAI-1 levels as an integrated endothelial response to severe burns. Burns. 2001; 27(6): 569–75. https://doi.org/10.1016/s0305-4179(01)00011-0.

31.

Lu RP, Ni A, Lin FC, Ortiz-Pujols SM, Adams SD, Monroe DM 3rd, et al. Major burn injury is not associated with acute traumatic coagulopathy. J Trauma Acute Care Surg. 2013;74(6):1474–9. https://doi.org/10.1097/TA.0b013e3182923193.CrossRefPubMedPubMedCentral

32.

Sherren PB, Hussey J, Martin R, Kundishora T, Parker M, Emerson B. Acute burn induced coagulopathy. Burns. 2013;39(6):1157–61. https://doi.org/10.1016/j.burns.2013.02.010.CrossRefPubMed

33.

Lippi G, Ippolito L, Cervellin G. Disseminated intravascular coagulation in burn injury. Semin Thromb Hemost. 2010;36(4):429–36. https://doi.org/10.1055/s-0030-1254051.CrossRefPubMed

34.

Kowal-Vern A, Walenga JM, Hoppensteadt D, Gamelli RL. Prothrombin fragment 1.2 and modified antithrombin as predictors of disseminated intravascular coagulation and thrombotic risk in thermal injury. J Burn Care Res. 2013; 34(4): 459–64. https://doi.org/10.1097/BCR.0b013e3182700659.

35.

Glas GJ, Levi M, Schultz MJ. Coagulopathy and its management in patients with severe burns. JTH. 2016;14(5):865–74. https://doi.org/10.1111/jth.13283.CrossRefPubMed

36.

Tagami T, Matsui H, Moroe Y, Fukuda R, Shibata A, Tanaka C, et al. Antithrombin use and 28-day in-hospital mortality among severe-burn patients: an observational nationwide study. Ann Intensive Care. 2017;7(1):18. https://doi.org/10.1186/s13613-017-0244-y.CrossRefPubMedPubMedCentral

37.

Lavrentieva A, Kontakiotis T, Bitzani M, Parlapani A, Thomareis O, Scourtis H, et al. The efficacy of antithrombin administration in the acute phase of burn injury. Thromb Haemost. 2008;100(2):286–90. https://doi.org/10.1160/TH07-11-0684.CrossRefPubMed

38.

Zayas GJ, Bonilla AM, Saliba MJ. Heparin reduced mortality and sepsis in severely burned children. Ann Burns Fire Disasters. 2007;20(1):29–34.PubMedPubMedCentral

39.

Maeda K, Hirota M, Ichihara A, Ohmuraya M, Hashimoto D, Sugita H, et al. Applicability of disseminated intravascular coagulation parameters in the assessment of the severity of acute pancreatitis. Pancreas. 2006;32(1):87–92. https://doi.org/10.1097/01.mpa.0000186248.89081.44.CrossRefPubMed

40.

Yang N, Zhang DL, Hao JY. Coagulopathy and the prognostic potential of D-dimer in hyperlipidemia-induced acute pancreatitis. Hepatobiliary Pancreat Dis Int. 2015;14(6):633–41. https://doi.org/10.1016/s1499-3872(15)60376-9.CrossRefPubMed

41.

Yang N, Hao J, Zhang D. Antithrombin III and D-dimer levels as indicators of disease severity in patients with hyperlipidaemic or biliary acute pancreatitis. J Inter Med Res. 2017;45(1):147–58. https://doi.org/10.1177/0300060516677929.CrossRef

42.

Ikarashi S, Kawai H, Hayashi K, Kohisa J, Sato T, Nozawa Y, et al. Risk factors for walled-off necrosis associated with severe acute pancreatitis: a multicenter retrospective observational study. J Hepatobiliary Pancreat Sci. 2020;27(11):887–95. https://doi.org/10.1002/jhbp.787.CrossRefPubMed

43.

Mole DJ, Olabi B, Robinson V, Garden OJ, Parks RW. Incidence of individual organ dysfunction in fatal acute pancreatitis: analysis of 1024 death records. HPB (Oxford). 2009;11(2):166–70. https://doi.org/10.1111/j.1477-2574.2009.00038.x.CrossRefPubMed

44.

Murata A, Okamoto K, Mayumi T, Muramatsu K, Matsuda S. The recent time trend of outcomes of disseminated intravascular coagulation in Japan: an observational study based on a national administrative database. J Thromb Thrombolysis. 2014;38(3):364–71. https://doi.org/10.1007/s11239-014-1068-3.CrossRefPubMed

45.

Ohbe H, Yamakawa K, Taniguchi K, Morita K, Matsui H, Fushimi K, et al. Underlying disorders, clinical phenotypes, and treatment diversity among patients with disseminated intravascular coagulation. JMA. 2020;3(4):321–9. https://doi.org/10.31662/jmaj.2020-0023.CrossRef

46.

Egi M, Ogura H, Yatabe T, Atagi K, Inoue S, Iba T, et al. The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2020 (J-SSCG 2020). J Intensive Care. 2021;9(1):53. https://doi.org/10.1186/s40560-021-00555-7.CrossRefPubMedPubMedCentral

47.

Eguchi T, Tsuji Y, Yamashita H, Fukuchi T, Kanamori A, Matsumoto K, et al. Efficacy of recombinant human soluble thrombomodulin in preventing walled-off necrosis in severe acute pancreatitis patients. Pancreatol. 2015;15(5):485–90. https://doi.org/10.1016/j.pan.2015.08.002.CrossRef

48.

Yano T, Taniguchi M, Shirasaka T, Tsuneyoshi I. Effectiveness of soluble recombinant human thrombomodulin in patients with severe acute pancreatitis complicated by disseminated intravascular coagulation. Turk J Anaesthesiol Reanim. 2019;47(4):320–6. https://doi.org/10.5152/tjar.2019.42709.CrossRefPubMedPubMedCentral

49.

Kerr R, Newsome P, Germain L, Thomson E, Dawson P, Stirling D, et al. Effects of acute liver injury on blood coagulation. J Thromb Haemost. 2003;1(4):754–9. https://doi.org/10.1046/j.1538-7836.2003.00194.x.CrossRefPubMed

50.

Arai M, Mochida S, Ohno A, Ogata I, Obama H, Maruyama I, et al. Blood coagulation equilibrium in rat liver microcirculation as evaluated by endothelial cell thrombomodulin and macrophage tissue factor. Thromb Res. 1995;80(2):113–23. https://doi.org/10.1016/0049-3848(95)00157-m.CrossRefPubMed

51.

Yamanobe F, Mochida S, Ohno A, Ishikawa K, Fujiwara K. Recombinant human tissue factor pathway inhibitor as a possible anticoagulant targeting hepatic sinusoidal walls. Thromb Res. 1997;85(6):493–501. https://doi.org/10.1016/s0049-3848(97)00038-8.CrossRefPubMed

52.

Mochida S, Arai M, Ohno A, Yamanobe F, Ishikawa K, Matsui A, et al. Deranged blood coagulation equilibrium as a factor of massive liver necrosis following endotoxin administration in partially hepatectomized rats. Hepatology. 1999;29(5):1532–40. https://doi.org/10.1002/hep.510290533.CrossRefPubMed

53.

Mochida S, Ohno A, Arai M, Tamatani T, Miyasaka M, Fujiwara K. Role of adhesion molecules in the development of massive hepatic necrosis in rats. Hepatology. 1996;23(2):320–8. https://doi.org/10.1053/jhep.1996.v23.pm0008591859.CrossRefPubMed

54.

Nakao M, Nakayama N, Uchida Y, Tomiya T, Ido A, Sakaida I, et al. Nationwide survey for acute liver failure and late-onset hepatic failure in Japan. J Gastroenterol. 2018;53(6):752–69. https://doi.org/10.1007/s00535-017-1394-2.CrossRefPubMed

55.

Mochida S, Nakayama N. Acute Liver Failure and Delayed Liver Failure (LOHF) in Japan (2020): 2021 National Survey. Ministry of Health, Labour and Welfare, Grant-in-Aid for Scientific Research (Intractable Disease Policy Research Project), “Research and Study on Intractable Liver and Biliary Diseases”. 2021.

56.

Asakura H, Takahashi H, Uchiyama T, Eguchi Y, Okamoto K, Kawasugi K. Japanese Society of Thrombosis and Haemostasis DIC Diagnostic Criteria, 2017 Edition. Jpn J Thromb Hemost. 2017; 28(3): 369–91. https://doi.org/10.2491/jjsth.28.369.

57.

Spadaro A, Tortorella V, Morace C, Fortiguerra A, Composto P, Bonfiglio C, et al. High circulating D-dimers are associated with ascites and hepatocellular carcinoma in liver cirrhosis. World J Gastroenterol. 2008;14(10):1549–52. https://doi.org/10.3748/wjg.14.1549.CrossRefPubMedPubMedCentral

58.

Ministry of Health Law, Research Group for Intractable Liver and Biliary Diseases. 2017.

59.

Langley PG, Hughes RD, Forbes A, Keays R, Williams R. Controlled trial of antithrombin III supplementation in fulminant hepatic failure. J Hepatol. 1993;17(3):326–31. https://doi.org/10.1016/s0168-8278(05)80213-2.CrossRefPubMed

60.

Fujiwara K, Okita K, Akamatsu K, Abe H, Tameda Y, Sakai T, et al. Antithrombin III concentrate in the treatment of fulminant hepatic failure. Gastroenterol Jpn. 1988;23(4):423–7. https://doi.org/10.1007/bf02779211.CrossRefPubMed

61.

Erez O, Othman M, Rabinovich A, Leron E, Gotsch F, Thachil J. DIC in Pregnancy - pathophysiology, clinical characteristics, diagnostic scores, and treatments. J Blood Med. 2022;13:21–44. https://doi.org/10.2147/jbm.S273047.CrossRefPubMedPubMedCentral

62.

Morikawa M, Nii M, Nakabayashi Y, Itakura A, Kobayashi T, Adachi T. Capacity of Japanese institutions to manage obstetrical disseminated intravascular coagulation in 2018: a national surveillance questionnaire and retrospective cohort study. J Obstet Gynaecol Res. 2021;47(9):3159–70. https://doi.org/10.1111/jog.14875.CrossRefPubMed

63.

Erez O, Mastrolia SA, Thachil J. Disseminated intravascular coagulation in pregnancy: insights in pathophysiology, diagnosis and management. Am J Obstet Gynecol. 2015;213(4):452–63. https://doi.org/10.1016/j.ajog.2015.03.054.CrossRefPubMed

64.

Montagnana M, Franchi M, Danese E, Gotsch F, Guidi GC. Disseminated intravascular coagulation in obstetric and gynecologic disorders. Semin Thromb Hemost. 2010;36(4):404–18. https://doi.org/10.1055/s-0030-1254049.CrossRefPubMed

65.

Cunningham FG, Nelson DB. Disseminated intravascular coagulation syndromes in obstetrics. Obstet Gynecol. 2015;126(5):999–1011. https://doi.org/10.1097/aog.0000000000001110.CrossRefPubMed

66.

Harris K, Proctor LK, Shinar S, Philippopoulos E, Yudin MH, Murphy KE. Outcomes and management of pregnancy and puerperal group A streptococcal infections: a systematic review. Acta Obstet Gynecol Scand. 2023;102(2):138–57. https://doi.org/10.1111/aogs.14500.CrossRefPubMedPubMedCentral

67.

Haram K, Mortensen JH, Mastrolia SA, Erez O. Disseminated intravascular coagulation in the HELLP syndrome: how much do we really know? J Matern Fetal Neonatal Med. 2017;30(7):779–88. https://doi.org/10.1080/14767058.2016.1189897.CrossRefPubMed

68.

Gomez-Tolub R, Rabinovich A, Kachko E, Benshalom-Tirosh N, Tirosh D, Thachil J, et al. Placental abruption as a trigger of DIC in women with HELLP syndrome: a population-based study. J Matern Fetal Neonatal Med. 2022;35(17):3259–69. https://doi.org/10.1080/14767058.2020.1818200.CrossRefPubMed

69.

Byrne JJ, Seasely A, Nelson DB, McIntire DD, Cunningham FG. Comparing acute fatty liver of pregnancy from hemolysis, elevated liver enzymes, and low platelets syndrome. J Matern Fetal Neonatal Med. 2022;35(7):1352–62. https://doi.org/10.1080/14767058.2020.1754790.CrossRefPubMed

70.

Sibai BM. Imitators of severe pre-eclampsia. Semin Perinatol. 2009;33(3):196–205. https://doi.org/10.1053/j.semperi.2009.02.004.CrossRefPubMed

71.

Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86(5):1327–30.CrossRefPubMed

72.

Erez O, Novack L, Beer-Weisel R, Dukler D, Press F, Zlotnik A, et al. DIC score in pregnant women–a population-based modification of the International Society on Thrombosis and Hemostasis score. PLoS ONE. 2014;9(4):e93240. https://doi.org/10.1371/journal.pone.0093240.CrossRefPubMedPubMedCentral

73.

Kobayashi T. Obstetrical disseminated intravascular coagulation score. J Obstet Gynaecol Res. 2014;40(6):1500–6. https://doi.org/10.1111/jog.12426.CrossRefPubMed

74.

Itakura A, Serizawa M, Takeda J, Takeda Y, Futai T, Hyodo H et al. Disseminated intravascular coagulation syndrome (DIC) in obstetrics; Provisional obstetric DIC diagnostic criteria. JJ Obstet Gynecol Neonat Hematol. 2023; 32(2): 43–9. http://search.jamas.or.jp/link/ui/2023153428(in Japanese)

75.

Morikawa M, Takeda Y, Matsunaga S, Makino S, Eto E, Serizawa M, et al. Effectiveness, reliability, and validity of new Japanese diagnostic criteria for obstetrical disseminated intravascular coagulation. Sci Rep. 2024;14(1):17677. https://doi.org/10.1038/s41598-024-68298-.CrossRefPubMedPubMedCentral

76.

Wikkelsø AJ, Edwards HM, Afshari A, Stensballe J, Langhoff-Roos J, Albrechtsen C, et al. Pre-emptive treatment with fibrinogen concentrate for post-partum haemorrhage: randomized controlled trial. Br J Anaesth. 2015;114(4):623–33. https://doi.org/10.1093/bja/aeu444.CrossRefPubMed

77.

Collins PW, Cannings-John R, Bruynseels D, Mallaiah S, Dick J, Elton C, et al. Viscoelastometric-guided early fibrinogen concentrate replacement during post-partum haemorrhage: OBS2, a double-blind randomized controlled trial. Br J Anaesth. 2017;119(3):411–21. https://doi.org/10.1093/bja/aex181.CrossRefPubMed

78.

Ducloy-Bouthors AS, Mercier FJ, Grouin JM, Bayoumeu F, Corouge J, Le Gouez A, et al. Early and systematic administration of fibrinogen concentrate in post-partum haemorrhage following vaginal delivery: the FIDEL randomised controlled trial. BJOG. 2021;128(11):1814–23. https://doi.org/10.1111/1471-0528.16699.CrossRefPubMed

79.

Mallaiah S, Barclay P, Harrod I, Chevannes C, Bhalla A. Introduction of an algorithm for ROTEM-guided fibrinogen concentrate administration in major obstetric haemorrhage. Anaesthesia. 2015;70(2):166–75. https://doi.org/10.1111/anae.12859.CrossRefPubMed

80.

McNamara H, Kenyon C, Smith R, Mallaiah S, Barclay P. Four years’ experience of a ROTEM(®) -guided algorithm for treatment of coagulopathy in obstetric haemorrhage. Anaesthesia. 2019;74(8):984–91. https://doi.org/10.1111/anae.14628.CrossRefPubMed

81.

Seto S, Itakura A, Okagaki R, Suzuki M, Ishihara O. An algorithm for the management of coagulopathy from post-partum hemorrhage, using fibrinogen concentrate as first-line therapy. Int J Obstet Anesth. 2017;32:11–6. https://doi.org/10.1016/j.ijoa.2017.03.005.CrossRefPubMed

82.

Ahmed S, Harrity C, Johnson S, Varadkar S, McMorrow S, Fanning R, et al. The efficacy of fibrinogen concentrate compared with cryoprecipitate in major obstetric haemorrhage–an observational study. Transfus Med. 2012;22(5):344–9. https://doi.org/10.1111/j.1365-3148.2012.01178.x.CrossRefPubMed

83.

Matsunaga S, Takai Y, Nakamura E, Era S, Ono Y, Yamamoto K, et al. The clinical efficacy of fibrinogen concentrate in massive obstetric haemorrhage with hypofibrinogenaemia. Sci Rep. 2017;7:46749. https://doi.org/10.1038/srep46749.CrossRefPubMedPubMedCentral

84.

Effect of early tranexamic acid administration on mortality. hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389(10084):2105–16. https://doi.org/10.1016/s0140-6736(17)30638-4.CrossRef

85.

Vogel JP, Oladapo OT, Dowswell T, Gülmezoglu AM. Updated WHO recommendation on intravenous tranexamic acid for the treatment of post-partum haemorrhage. Lancet Glob Health. 2018;6(1):e18–9. https://doi.org/10.1016/s2214-109x(17)30428-x.CrossRefPubMed

86.

Ducloy-Bouthors AS, Jude B, Duhamel A, Broisin F, Huissoud C, Keita-Meyer H, et al. High-dose tranexamic acid reduces blood loss in post-partum haemorrhage. Crit Care. 2011;15(2):R117. https://doi.org/10.1186/cc10143.CrossRefPubMedPubMedCentral

87.

Sahhaf F, Abbasalizadeh S, Ghojazadeh M, Velayati A, Khandanloo R, Saleh P, et al. Comparison effect of intravenous tranexamic acid and misoprostol for post-partum haemorrhage. Niger Med J. 2014;55(4):348–53. https://doi.org/10.4103/0300-1652.137228.CrossRefPubMedPubMedCentral

88.

Diop A, Abbas D, Ngoc NTN, Martin R, Razafi A, Tuyet HTD, et al. A double-blind, randomized controlled trial to explore oral tranexamic acid as adjunct for the treatment for post-partum hemorrhage. Reprod Health. 2020;17(1):34. https://doi.org/10.1186/s12978-020-0887-2.CrossRefPubMedPubMedCentral

89.

Ducloy-Bouthors AS, Gilliot S, Kyheng M, Faraoni D, Turbelin A, Keita-Meyer H, et al. Tranexamic acid dose-response relationship for antifibrinolysis in post-partum haemorrhage during Caesarean delivery: TRACES, a double-blind, placebo-controlled, multicentre, dose-ranging biomarker study. Br J Anaesth. 2022;129(6):937–45. https://doi.org/10.1016/j.bja.2022.08.033.CrossRefPubMedPubMedCentral

90.

Stämpfli D, Weiler S, Weiniger CF, Burden AM, Heesen M. Renal ischemic adverse drug events related to tranexamic acid in women of child-bearing age: an analysis of pharmacovigilance data. Eur J Clin Pharmacol. 2021;77(6):913–9. https://doi.org/10.1007/s00228-020-03064-y.CrossRefPubMed

91.

Sentilhes L, Sénat MV, Le Lous M, Winer N, Rozenberg P, Kayem G, et al. Tranexamic acid for the prevention of blood loss after cesarean delivery. N Eng J Med. 2021;384(17):1623–34. https://doi.org/10.1056/NEJMoa2028788.CrossRef

92.

Sentilhes L, Madar H, Le Lous M, Sénat MV, Winer N, Rozenberg P et al. Tranexamic acid for the prevention of blood loss after cesarean among women with twins: a secondary analysis of the TRAnexamic Acid for Preventing Post-partum Hemorrhage Following a Cesarean Delivery randomized clinical trial. Am J Obstet Gynecol.. 2022; 227(6): 889.e1-.e17. https://doi.org/10.1016/j.ajog.2022.06.019.

93.

Pacheco LD, Clifton RG, Saade GR, Weiner SJ, Parry S, Thorp JM Jr, et al. Tranexamic acid to prevent obstetrical hemorrhage after cesarean delivery. N Eng J Med. 2023;388(15):1365–75. https://doi.org/10.1056/NEJMoa2207419.CrossRef

94.

Schwickert A, van Beekhuizen HJ, Bertholdt C, Fox KA, Kayem G, Morel O, et al. Association of peripartum management and high maternal blood loss at cesarean delivery for placenta accreta spectrum (PAS): a multinational database study. Acta Obstet Gynecol Scand. 2021;100(Suppl 1):29–40. https://doi.org/10.1111/aogs.14103.CrossRefPubMed

95.

Martí-Carvajal AJ, Comunián-Carrasco G, Peña-Martí GE. Haematological interventions for treating disseminated intravascular coagulation during pregnancy and post-partum. Cochrane Database Sys Rev. 2011; 2011(3): Cd008577. https://doi.org/10.1002/14651858.CD008577.pub2.

96.

Iwasaki Y, Ohbe H, Shigemi D, Fushimi K, Yasunaga H. Effect of antithrombin III among patients with disseminated intravascular coagulation in obstetrics: a nationwide observational study in Japan. BJOG. 2022;129(5):805–11. https://doi.org/10.1111/1471-0528.16938.CrossRefPubMed

97.

Maki M, Terao T, Ikenoue K, Fujimoto S, Kudo R, Nishitani I et al. Therapeutic efficacy of antithrombin III concentrate in obstetric DIC: results of a multicenter study. JJ Obstet Gynecol Neonat Hematol. 1994; 4(1): 37–49. http://search.jamas.or.jp/link/ui/1994184524 (in Japanese)

98.

Maki M, Terao T, Ikenoue T, Takemura T, Sekiba K, Shirakawa K et al. Clinical evaluation of antithrombin III concentrate (BI 6.013) for disseminated intravascular coagulation in obstetrics. Well-controlled multicenter trial. Gynecol Obstet Invest. 1987; 23(4): 230–40. https://doi.org/10.1159/000298866.

99.

Murata M, Hayakawa M, Goto K, Isobe K, Matuura T, Hirano H, et al. Anticoagulant therapy in obstetrical disorders. JJ Clin Hematol. 1990;31(6):763–8. https://doi.org/10.11406/rinketsu.31.763(inJapanese).CrossRef

100.

Kobayashi T, Kajiki M, Nihashi K, Honda G. Surveillance of the safety and efficacy of recombinant human soluble thrombomodulin in patients with obstetrical disseminated intravascular coagulation. Thromb Res. 2017;159:109–15. https://doi.org/10.1016/j.thromres.2017.08.017.CrossRefPubMed

101.

Sugawara J, Suenaga K, Hoshiai T, Sato T, Nishigori H, Nagase S, et al. Efficacy of recombinant human soluble thrombomodulin in severe post-partum hemorrhage with disseminated intravascular coagulation. Clin Appl Thromb Hemost. 2013;19(5):557–61. https://doi.org/10.1177/1076029612443305.CrossRefPubMed

102.

Yoshihara M, Uno K, Tano S, Mayama M, Ukai M, Kondo S, et al. The efficacy of recombinant human soluble thrombomodulin for obstetric disseminated intravascular coagulation: a retrospective study. Crit Care. 2015;19:369. https://doi.org/10.1186/s13054-015-1086-3.CrossRefPubMedPubMedCentral

103.

Ahonen J, Jokela R, Korttila K. An open non-randomized study of recombinant activated factor VII in major post-partum haemorrhage. Acta Anaesthesiol Scand. 2007;51(7):929–36. https://doi.org/10.1111/j.1399-6576.2007.01323.x.CrossRefPubMed

104.

Hossain N, Shansi T, Haider S, Soomro N, Khan NH, Memon GU, et al. Use of recombinant activated factor VII for massive post-partum hemorrhage. Acta Obstet Gynecol Scand. 2007;86(10):1200–6. https://doi.org/10.1080/00016340701619324.CrossRefPubMed

105.

Kobayashi T, Nakabayashi M, Yoshioka A, Maeda M, Ikenoue T. Recombinant activated factor VII (rFVIIa/NovoSeven®) in the management of severe post-partum haemorrhage: initial report of a multicentre case series in Japan. Int J Hematol. 2012;95(1):57–63. https://doi.org/10.1007/s12185-011-0974-9.CrossRefPubMed

106.

Lavigne-Lissalde G, Aya AG, Mercier FJ, Roger-Christoph S, Chauleur C, Morau E, et al. Recombinant human FVIIa for reducing the need for invasive second-line therapies in severe refractory post-partum hemorrhage: a multicenter, randomized, open controlled trial. J Thromb Haemost. 2015;13(4):520–9. https://doi.org/10.1111/jth.12844.CrossRefPubMed

107.

Murakami M, Kobayashi T, Kubo T, Hata T, Takeda S, Masuzaki H. Experience with recombinant activated factor VII for severe post-partum hemorrhage in Japan, investigated by Perinatology Committee, Japan Society of Obstetrics and Gynecology. J Obstet Gynaecol Res. 2015;41(8):1161–8. https://doi.org/10.1111/jog.12712.CrossRefPubMed

108.

Park SC, Yeom SR, Han SK, Jo YM, Kim HB. Recombinant activated factor VII as a second line treatment for post-partum hemorrhage. Korean J Crit Care Med. 2017;32(4):333–9. https://doi.org/10.4266/kjccm.2016.00787.CrossRefPubMedPubMedCentral

109.

Kimura H. Chronic active EB virous infection. J Hematopoiet Cell Transpl. 2021;10(2):87–93. https://doi.org/10.7889/hct-20-026.CrossRef

110.

Alotaibi Y, Albogami M, Alsaedy A, Khubrani R, Al AB. A lethal manifestation of chronic active epstein-barr virus infection: a case report. Cureus. 2022;14(10):e30158. https://doi.org/10.7759/cureus.30158.CrossRefPubMedPubMedCentral

111.

Kimura H, Morishima T, Kanegane H, Ohga S, Hoshino Y, Maeda A, et al. Prognostic factors for chronic active Epstein-Barr virus infection. J Infect Dis. 2003;187(4):527–33. https://doi.org/10.1086/367988.CrossRefPubMed

112.

Kimura H, Cohen JI. Chronic active epstein-barr virus disease. Front Immunol. 2017;8:1867. https://doi.org/10.3389/fimmu.2017.01867.CrossRefPubMedPubMedCentral

113.

Guidelines for the Treatment of Chronic Active EV Virus Infection and Related Diseases. https://www.jspid.jp/wp-content/uploads/2021/10/guideline_EB_virus.pdf.

114.

Yamamoto M, Hori T, Hatakeyama N, Igarashi K, Inazawa N, Tsutsumi H, et al. Use of recombinant thrombomodulin in disseminated intravascular coagulation complicated hemophagocytic lymphohistiocytosis. Indian J Pediatr. 2014;81(3):288–91. https://doi.org/10.1007/s12098-013-1145-1.CrossRefPubMed

115.

Saevels K, Robert D, Van den Broeck S, Malfait R, Gadisseur A, Jorens P, et al. EBV-associated hemophagocytic lymphohistiocytosis complicated by severe coagulation disorders and opportunistic infections: case report of a survivor. Clin Case Rep. 2018;6(1):115–8. https://doi.org/10.1002/ccr3.1301.CrossRefPubMed

116.

Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet. 2011;377(9768):849–62. https://doi.org/10.1016/s0140-6736(10)60667-8.CrossRefPubMedPubMedCentral

117.

Gholizadeh O, Jafari MM, Zoobinparan R, Yasamineh S, Tabatabaie R, Akbarzadeh S, et al. Recent advances in treatment Crimean-Congo hemorrhagic fever virus: a concise overview. Microb Pathog. 2022;169:105657. https://doi.org/10.1016/j.micpath.2022.105657.CrossRefPubMed

118.

Hunter N, Rathish B. Marburg Fever. StatPearls. Treasure Island (FL): StatPearls Publishing 2022 Jan.

119.

Houlihan C, Behrens R. Lassa fever Bmj. 2017;358:j2986. https://doi.org/10.1136/bmj.j2986.CrossRefPubMed

120.

Flórez-Álvarez L, de Souza EE, Botosso VF, de Oliveira DBL, Ho PL, Taborda CP, et al. Hemorrhagic fever viruses: pathogenesis, therapeutics, and emerging and re-emerging potential. Front Microbiol. 2022;13:1040093. https://doi.org/10.3389/fmicb.2022.1040093.CrossRefPubMedPubMedCentral

121.

Ozkurt Z, Ozden K, Kiki I, Usanmaz M. Prognostic significance of antithrombin activity in patients with crimean-congo hemorrhagic Fever. Eurasian J Med. 2011;43(2):83–6. https://doi.org/10.5152/eajm.2011.19.CrossRefPubMedPubMedCentral

122.

Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383(2):120–8. https://doi.org/10.1056/NEJMoa2015432.CrossRefPubMedPubMedCentral

123.

Schulman S, Sholzberg M, Spyropoulos AC, Zarychanski R, Resnick HE, Bradbury CA, et al. ISTH guidelines for antithrombotic treatment in COVID-19. J Thromb Haemost. 2022;20(10):2214–25. https://doi.org/10.1111/jth.15808.CrossRefPubMedPubMedCentral

124.

Griffin G, Shenoi S, Hughes GC. Hemophagocytic lymphohistiocytosis: an update on pathogenesis, diagnosis, and therapy. Best Pract Res Clin Rheumatol. 2020;34(4):101515. https://doi.org/10.1016/j.berh.2020.101515.CrossRefPubMed

125.

Kim B, Choi YW, Pai H, Kim J. A case of human immunodeficiency virus-triggered hemophagocytic lymphohistocytosis presenting with severe bleeding tendency. Infect Chemother. 2021;53(4):802–7. https://doi.org/10.3947/ic.2018.0203.CrossRefPubMed

126.

Kuki I, Shiomi M, Okazaki S, Kawawaki H, Tomiwa K, Amo K, et al. Characteristic neuroradiologic features in hemorrhagic shock and encephalopathy syndrome. J Child Neurol. 2015;30(4):468–75. https://doi.org/10.1177/0883073814558119.CrossRefPubMed

127.

Xu B, Liu L, Huang X, Ma H, Zhang Y, Du Y, et al. Metagenomic analysis of fever, thrombocytopenia and leukopenia syndrome (FTLS) in Henan Province, China: discovery of a new bunyavirus. PLoS Pathog. 2011;7(11):e1002369. https://doi.org/10.1371/journal.ppat.1002369.CrossRefPubMedPubMedCentral

128.

Noguchi M, Oshita S, Yamazoe N, Miyazaki M, Takemura YC. Important clinical features of japanese spotted fever. Am J Trop Med Hyg. 2018;99(2):466–9. https://doi.org/10.4269/ajtmh.17-0576.CrossRefPubMedPubMedCentral

129.

Lee HC, Ko WC, Lee HL, Chen HY. Clinical manifestations and complications of rickettsiosis in southern Taiwan. J Formos Med Assoc. = Taiwan yi zhi. 2002; 101(6): 385–92.

130.

Gao S, Li L, Zhou X, Dai X, Lu L, Chen Y, et al. Fatal Rickettsia Japonica infection complicating disseminated intravascular coagulation in Yichang. China Infect Drug Resist. 2022;15:6613–23. https://doi.org/10.2147/idr.S383917.CrossRefPubMed

131.

Athanassopoulou P, Liatsos G, Pirounaki M, Skounakis M, Moulakakis A. Disseminated intravascular coagulation as the laboratory hallmark of acute Q fever. Diagn Microbiol Infect Dis. 2011;69(2):210–2. https://doi.org/10.1016/j.diagmicrobio.2010.08.022.CrossRefPubMed

132.

Stevenson S, Gowardman J, Tozer S, Woods M. Life-threatening Q fever infection following exposure to kangaroos and wallabies. BMJ Case Rep. 2015. https://doi.org/10.1136/bcr-2015-210808.CrossRefPubMedPubMedCentral

133.

Lalloo DG, Shingadia D, Bell DJ, Beeching NJ, Whitty CJM, Chiodini PL. UK malaria treatment guidelines 2016. J Infect. 2016;72(6):635–49. https://doi.org/10.1016/j.jinf.2016.02.001.CrossRefPubMedPubMedCentral

134.

Wagenaar JF, Goris MG, Partiningrum DL, Isbandrio B, Hartskeerl RA, Brandjes DP, et al. Coagulation disorders in patients with severe leptospirosis are associated with severe bleeding and mortality. Trop Med Int Health. 2010;15(2):152–9. https://doi.org/10.1111/j.1365-3156.2009.02434.x.CrossRefPubMed

135.

Fernandes LGV, Filho AFS, Souza GO, Vasconcellos SA, Romero EC, Nascimento A. Decrease in antithrombin III and prothrombin serum levels contribute to coagulation disorders during leptospirosis. Microbiology (Reading). 2016;162(8):1407–21. https://doi.org/10.1099/mic.0.000318.CrossRefPubMed

136.

Doi O, Takada Y, Yamauchi Y, Ogawa T. Systemic candidiasis with DIC and candida endophthalmitis in a postoperative neonate. Aust Paediatr J. 1989; 25(6): 372–5. https://doi.org/10.1111/j.1440-1754.1989.tb02362.x.

137.

Takayama Y, Kubota T, Ogino Y, Ohnishi H, Togitani K, Yokoyama A. TAFRO syndrome with disseminated intravascular coagulation successfully treated with tocilizumab and recombinant thrombomodulin. Intern Med. 2018;57(9):1291–6. https://doi.org/10.2169/internalmedicine.9484-17.CrossRefPubMed

138.

Tokashiki T, Hashiguchi T, Arimura K, Eiraku N, Maruyama I, Osame M. Predictive value of serial platelet count and VEGF determination for the management of DIC in the Crow-Fukase (POEMS) syndrome. Inter Med. 2003;42(12):1240–3. https://doi.org/10.2169/internalmedicine.42.1240.CrossRef

139.

Komori K, Konishi M, Maruta Y, Toriba M, Sakai A, Matsuda A, et al. Characterization of a novel metalloproteinase in Duvernoy’s gland of Rhabdophis tigrinus tigrinus. J Toxicol Sci. 2006;31(2):157–68. https://doi.org/10.2131/jts.31.157.CrossRefPubMed

140.

Komori Y, Hifumi T, Yamamoto A, Sakai A, Ato M, Sawabe K et al. Comparative Study of Biological Activities of Venom from Colubrid Snakes Rhabdophis tigrinus (Yamakagashi) and Rhabdophis lateralis. Toxins (Basel). 2017; 9(11). https://doi.org/10.3390/toxins9110373.

141.

Ichiki T, Kohda F, Hiramatsu T, Saiki R, Sakai A, Furue M. Early pathology in venom-induced consumption coagulopathy by Rhabdophis tigrinus (Yamakagashi snake) envenomation. Clin Toxicol (Philadelphia). 2019;57(7):668–71. https://doi.org/10.1080/15563650.2018.1540045.CrossRef

142.

Hifumi T, Sakai A, Yamamoto A, Murakawa M, Ato M, Shibayama K, et al. Effect of antivenom therapy of Rhabdophis tigrinus (Yamakagashi snake) bites. J Intensive Care. 2014;2(1):44. https://doi.org/10.1186/s40560-014-0044-5.CrossRefPubMedPubMedCentral

143.

Hifumi T, Sakai A, Kondo Y, Yamamoto A, Morine N, Ato M, et al. Venomous snake bites: clinical diagnosis and treatment. J Intensive Care. 2015;3(1):16. https://doi.org/10.1186/s40560-015-0081-8.CrossRefPubMedPubMedCentral

144.

Hifumi T, Sakai A, Yamamoto A, Murakawa M, Ato M, Shibayama K, et al. Clinical characteristics of yamakagashi (Rhabdophis tigrinus) bites: a national survey in Japan, 2000–2013. J Intensive Care. 2014;2(1):19. https://doi.org/10.1186/2052-0492-2-19.CrossRefPubMedPubMedCentral

145.

Ichiki T, Kohda F, Hiramatsu T, Saiki R, Sakai A, Furue M. Early pathology in venom-induced consumption coagulopathy by Rhabdophis tigrinus (Yamakagashi snake) envenomation. Clin Toxicol (Phila). 2019;57(7):668–71. https://doi.org/10.1080/15563650.2018.1540045.CrossRefPubMed

146.

Hifumi T, Murakawa M, Sakai A, Ginnaga A, Yamamoto A, Ato M, et al. Potentially fatal coagulopathy secondary to yamakagashi (Rhabdophis tigrinus) bites that completely recovered with antivenom treatment. Acute Med Surg. 2015;2(2):123–6. https://doi.org/10.1002/ams2.69.CrossRefPubMed

147.

Wu J, Gong X, Hu Z, Sun Q. Acute liver failure caused by Amanita verna: a case series and review of the literature. BMC Surg. 2021;21(1):436. https://doi.org/10.1186/s12893-021-01434-6.CrossRefPubMedPubMedCentral

148.

Wennig R, Eyer F, Schaper A, Zilker T, Andresen-Streichert H. Mushroom poisoning. Dtsch Arztebl Int. 2020;117(42):701–8. https://doi.org/10.3238/arztebl.2020.0701.CrossRefPubMedPubMedCentral

149.

Sanz P, Reig R, Borrás L, Martínez J, Máñez R, Corbella J. Disseminated intravascular coagulation and mesenteric venous thrombosis in fatal Amanita poisoning. Hum Toxicol. 1988;7(2):199–201. https://doi.org/10.1177/096032718800700218.CrossRefPubMed

150.

Soysal D, Cevik C, Saklamaz A, Yetimalar Y, Unsal B. Coagulation disorders secondary to acute liver failure in Amanita phalloides poisoning: a case report. Turk J Gastroenterol. 2006;17(3):198–202.PubMed

151.

Lai D, Tian Y, Zhang J, Weng CF. Hyperendogenous heparinization suggests a guideline for the management of massive wasp stings in two victims. Wilderness Environ Med. 2021;32(3):344–50. https://doi.org/10.1016/j.wem.2021.02.009.CrossRefPubMed

152.

Wang JL, Shen EY, Ho MY. Isolated prolongation of activated partial thromboplastin time following wasp sting. Acta Paediatr Taiwan. 2005;46(3):164–5.PubMed

153.

Alberti A, Mancin M, Cortinovis D, Bidoli P, Sala L. Disseminated intravascular coagulation in advanced lung adenocarcinoma during first-line pembrolizumab. Immunotherapy. 2020;12(9):629–33. https://doi.org/10.2217/imt-2020-0018.CrossRefPubMed

154.

Ikezoe T. Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies. Int J Hematol. 2021;113(1):34–44. https://doi.org/10.1007/s12185-020-02992-w.CrossRefPubMed

Title: Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024: part 4—trauma, burn, obstetrics, acute pancreatitis/liver failure, and others
Authors: Mineji Hayakawa
Yoshinobu Seki
Takayuki Ikezoe
Kazuma Yamakawa
Kohji Okamoto
Shigeki Kushimoto
Yuichiro Sakamoto
Yuki Itagaki
Yuki Takahashi
Hiroyasu Ishikura
Toshihiko Mayumi
Toshihisa Tamura
Kenji Nishio
Yu Kawazoe
Ayami Shigeno
Yudai Takatani
Akihito Tampo
Yoshihiko Nakamura
Katsunori Mochizuki
Noritaka Yada
Kaoru Kawasaki
Akira Kiyokawa
Mamoru Morikawa
Mitsuhiro Uchiba
Takeshi Matsumoto
Hidesaku Asakura
Seiji Madoiwa
Toshimasa Uchiyama
Shinya Yamada
Shin Koga
Takashi Ito
Toshiaki Iba
Noriaki Kawano
Satoshi Gando
Hideo Wada
Committee of the Clinical Practice Guidelines for Disseminated Intravascular Coagulation 2024, the Japanese Society on Thrombosis, Hemostasis
Publication date: 31-01-2025
Publisher: Springer Nature Singapore
Keywords: Disseminated Intravascular Coagulation
Acute Pancreatitis
Tranexamic Acid
Acute Liver Failure
Fibrinolytic Therapy
Pancreatitis
Hepatitis
Published in: International Journal of Hematology
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-025-03918-0

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

12-12-2024
Lymphoma
News

Combining tafasitamab with lenalidomide and rituximab significantly improves progression-free survival for patients with relapsed or refractory follicular lymphoma.

Featuring the official presentation video

12-12-2024
Mantle Cell Lymphoma
News

Add-on blinatumomab improves DFS in children with ALL

Promising response to loncastuximab tesirine in lymphoma

12-12-2024
Lymphoma
News

» View more highlights on the ASH 2024 hub page

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Targeted Therapy
On-demand webinar

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Keynote series | Spotlight on menopause

Springer Medicine

Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024: part 4—trauma, burn, obstetrics, acute pancreatitis/liver failure, and others

Abstract

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Transplantation can be omitted for certain MCL patients

Add-on blinatumomab improves DFS in children with ALL

Promising response to loncastuximab tesirine in lymphoma

» View more highlights on the ASH 2024 hub page

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Keynote series | Spotlight on menopause

Springer Medicine

Abstract

Please log in to get access to this content

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Transplantation can be omitted for certain MCL patients

Add-on blinatumomab improves DFS in children with ALL

Promising response to loncastuximab tesirine in lymphoma

» View more highlights on the ASH 2024 hub page

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma